Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (401-410 of 709) with videos related to

Pageof 71
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 8, 2017
A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel diseaseAtsushi Funatsu, Shigeru Nakamura, Naoto Inoue, et al.
International Journal of Cardiology|May 17, 2018
Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group studySatoshi Yasuda, Koichi Kaikita, Hisao Ogawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 11, 2007
[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]Hiroaki Nagano, Atsushi Miyamoto, Hiroshi Wada, et al.
Journal of Gastroenterology|December 13, 2006
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alphaMasato Nakamura, Hiroaki Nagano, Hiroshi Wada, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|October 25, 2014
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary interventionTakaaki Isshiki, Takeshi Kimura, Hisao Ogawa, et al.
American Heart Journal|January 12, 2022
One-year outcome after percutaneous coronary intervention in nonagenarians: Insights from the J-PCI OUTCOME registryKanichi Otowa, Shun Kohsaka, Mitsuaki Sawano, et al.
BMC Medicine|February 25, 2022
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trialKunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 7, 2020
High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registryMasato Nakamura, Kazushige Kadota, Koichi Nakao, et al.
Journal of the American College of Cardiology|September 11, 2020
Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017Taku Inohara, Shun Kohsaka, John A Spertus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Use of 11p15 mucins as prognostic factors in small adenocarcinoma of the lungNoboru Nishiumi, Yoshiyuki Abe, Yoshimasa Inoue, et al.
Pageof 71

Showing results (401-410 of 709) with videos related to

Sort By:
Pageof 71
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 8, 2017
A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel diseaseAtsushi Funatsu, Shigeru Nakamura, Naoto Inoue, et al.
International Journal of Cardiology|May 17, 2018
Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group studySatoshi Yasuda, Koichi Kaikita, Hisao Ogawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 11, 2007
[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]Hiroaki Nagano, Atsushi Miyamoto, Hiroshi Wada, et al.
Journal of Gastroenterology|December 13, 2006
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alphaMasato Nakamura, Hiroaki Nagano, Hiroshi Wada, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|October 25, 2014
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary interventionTakaaki Isshiki, Takeshi Kimura, Hisao Ogawa, et al.
American Heart Journal|January 12, 2022
One-year outcome after percutaneous coronary intervention in nonagenarians: Insights from the J-PCI OUTCOME registryKanichi Otowa, Shun Kohsaka, Mitsuaki Sawano, et al.
BMC Medicine|February 25, 2022
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trialKunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 7, 2020
High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registryMasato Nakamura, Kazushige Kadota, Koichi Nakao, et al.
Journal of the American College of Cardiology|September 11, 2020
Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017Taku Inohara, Shun Kohsaka, John A Spertus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Use of 11p15 mucins as prognostic factors in small adenocarcinoma of the lungNoboru Nishiumi, Yoshiyuki Abe, Yoshimasa Inoue, et al.
Pageof 71